Defense World
26 Jul 2026, 05:59 UTC · 9w ago
Verdict
Headline takes no side. We score IFRX +0.60 across five claims — strongly bullish.
+0.60strongly bullish
More positive than 77% of ticker scores this week
Scored by the NIS engine · methodology.
What the story claims
5 claims · scored −1 bearish … +1 bullish
Analysts set a consensus target price for InflaRx (IFRX) of $7.00, implying a potential upside of 302.30%.
More positive than 93% of claims this week
Analysts set a consensus target price for Kamada (KMDA) of $13.00, suggesting a potential upside of 84.14%.
So whatSignificant positive price target indicates strong fundamental support, though less aggressive than IFRX.
Continue reading
5 related stories
Top 3 movers · tap to explore
More positive than 79% of claims this week
InflaRx exhibits high volatility with a beta of 2.44, compared to Kamada's beta of 0.85.
More negative than 70% of claims this week
Institutional ownership is significantly higher in InflaRx (42.4%) than in Kamada (20.4%).
More positive than 53% of claims this week
Kamada currently maintains higher gross revenue and earnings compared to InflaRx.
More positive than 44% of claims this week
Which stocks this story touches
More positive than 77% of ticker scores this week
Analysts suggest a significant potential upside of 302.30%, making it a more favorable investment according to the text.
More positive than 61% of ticker scores this week
Company beats InflaRx on 9 of 15 factors and has higher revenue and earnings.
More positive than 56% of ticker scores this week
Receives a positive average price target from analysts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
43m ago
More positive than 7% of relationship scores this week
[a_to_b] InflaRx has a supply agreement with Merck & Co. Inc.
−0.3%
Price flat so far
$1.74 vs $1.74 close before publication (Jul 24) · not market-adjusted
IFRX chart →
